Nasdaq:US$11.07 (+0.09) | HKEX:HK$17.62 (-0.09) | AIM:£1.65 (-0.05)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)